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ABSTRACT 
THE ROLE OF ADV AN CED GL YCOSYLA TED END PRODUCTS IN THE 
STIMULATION OF SIGNALING PATHWAYS IN FIBROBLAST APOPTOSIS 
AND THE PROPOSED ASSOCIATION WITH THE FORMATION OF TYPE II 
DIABETES MELLITUS WOUND HEALING COMPLICATIONS 
CHRISTINE M. MACLELLAN-MELITO, D.M.D 
Boston University, Goldman School of Dental Medicine 2005 
Major Professor: Dana T. Graves, DDS, DMSc 
Background 
Advanced glycosylation end products (AGEs) have been implicated in multi-organ 
diabetic complications including artherosclerosis, nephropathy, neuropathy, retinopathy, 
and decreased wound healing. AG Es aggregate as a result of increased glycation 
modifications, which occur during chronic hyperglycemic states such as diabetes. 
Accumulation of these by-products consequently allows for the formation of free 
radicals, which is believed to contribute to apoptotic events that lead to tissue destruction 
and thus systemic complications seen in diabetic patients. The goal of this study was to 
investigate signaling pathways by which AGE induced fibroblast apoptosis occurs and 
the proposed association with type II diabetes mellitus wound healing complications. 
Methods 
Protein extraction was performed on AGE stimulated fibroblasts at two time points in 
order to perform western blot analysis, which was used to evaluate the effect of AGE on 
specific kinase activities. Based on these results, an inhibitor study was designed to study 
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kinases specific signaling pathways including p38, JNK, ERK, and Akt. These kinases 
displayed significant changes in phosphorylation activity when stimulated with AGE in 
comparison to control collagen. Each inhibitor tested was compared to untreated 
fibroblasts and AGE stimulated fibroblasts. Fibroblasts were treated with kinase specific 
inhibitors 1 hour prior to AGE stimulation. Optical density was then measured after 24 
hours of treatment using an apoptosis assay, which indicated the amount of apoptosis 
present in treated cells. 
Results 
We determined that fibroblast apoptosis occurs through both the JNK and p38 pathways, 
while cell survival occurs through the Akt/PI3K pathway. The data obtained in this study 
indicates that ERK has little role in cell survival or apoptosis in the dermal fibroblast. To 
our knowledge, this is the first study in which the involvement of intracellular pathways 
in the adult dermal fibroblast apoptosis has been documented. 
Conclusion 
Although we have identified the pathways through which apoptosis occurs in the 
fibroblast, the mechanisms by which this occurs still remains unclear. Since fibroblasts 
are essential for proper wound healing, identification of the pathways by which fibroblast 
apoptosis occurs is promising data. This study represents a stepping-stone in 
understanding the exact mechanisms behind the decreased wound healing seen in the 
diabetic patient. 
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Introduction 
Diabetes 
A. Epidemiology of Diabetes 
Diabetes prevalence has reached concerning levels worldwide. According to the Center 
for Disease Control (CDC) and the American Diabetes Association, the prevalence of 
diabetes in the United States alone in 2005 was 20.8 million people or 7% of the 
population. 125 Of this number, it is presumed that 6.2 million people in the U.S. have not 
yet been diagnosed with the disease. Diabetic complications remain a major health risk 
as epidemiological studies have shown that the disease was the sixth leading cause of 
death in the United States in the year two thousand. As the country is in the midst of an 
obesity epidemic, the public must begin to comprehend the severity of diabetes and its 
subsequent ramifications. Not only does the disease pose serious health concerns, but it 
also results in astronomical health care costs. The total annual costs attributable to 
diabetes were estimated to be nearly 132 billion dollars in 2002, which accounts for 11 % 
of all health care expenditures in the U.S. 1 Obesity will only continue to contribute to 
the rise in diabetes prevalence since it is estimated that 90-95% of those with diabetes 
have Type II (NIDDM), while only 5-10% have Type I (IDDM). 2 These statistics 
indicate how crucial diabetic research, in particular Type II diabetes, is in controlling the 
disease and preventing it from remaining a disease of epidemic proportions. 
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B. Pathophysio/ogy of Type II diabetes 
For the maintenance of glucose homeostasis, normal tissue sensitivity to insulin is 
imperative.3 Type II diabetes (T2DM), formerly known as non-insulin dependent diabetes 
mellitus (NIDDM), is a condition of impaired sensitivity to insulin production by 
pancreatic beta cells and causes a hyperglycemic state. Obesity remains the major 
contributing factor for developing insulin resistance, and thus poorly controlled blood 
glucose levels in type 2 diabetics. Despite our limited understanding of the underlying 
pathophysiology, new and powerful tools for probing the molecular, genetic, and 
pathophysiological basis of glucose and energy homeostasis have provided key insights 
into the molecular basis of diabetes. 4 Researchers have articulated theories of 
mitochondrial and genetic mutations as well as biochemical mechanisms as possible 
etiologies of the decreased beta cell insulin production seen in T2DM. Completely 
comprehending this condition, however, will continue to require years of advanced 
diabetic research. What we do know is that insulin resistance is associated with oxidative 
stress, and although there is substantial evidence that hyperglycemia results in the 
generation of reactive oxygen species (ROS) and increased oxidant stress in the late 
complications of diabetes, the role of ROS in the development of insulin resistance, 
especially at the whole-body level, has recently been proposed. 5 A promising basis of 
future diabetic research may be developing knowledge of the role with which reactive 
oxygen species have in resistance. However, until we are able to fully explain the 
mechanisms behind insulin resistance, researchers must focus on studying how to treat 
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diabetics appropriately to avoid diabetic complications such as neuropathy, retinopathy, 
end stage renal disease and impaired wound healing. 
C. Diabetes and wound healing 
A well-established association exists between diabetes mellitus and diminished wound 
healing. Wound healing is an intricate process involving the communication and 
interaction between fibroblasts, endothelial cells, keratinocytes, inflammatory cells, and 
the extracellular matrix. 11 Although the exact mechanisms are not well understood, 
studies show that diabetes impairs numerous components of tissue repair including, 
hemostasis and inflammation, matrix deposition, and angiogenesis. 7 Non-compromised 
patients exhibit cellular infiltrate including platelets, neutrophils, mononuclear cells, and 
fibroblasts in response to injury. The proportion of cells change in three stages of wound 
healing that include the (i) acute inflammatory phase, (ii) proliferative phase and (iii) 
remodeling phase. 10 When injury ensues, the body mounts an immune response, thus 
resulting in blood vessel constriction and activation of hemostatic events. The 
inflammatory phase is initiated when exposed collagen during wound formation activates 
the clotting cascade (both the intrinsic and extrinsic pathways), and therefore leads to the 
release of potent vasoconstrictors such as thromboxane A2 and prostaglandin 2-alpha by 
damaged cell membranes. 94 Simultaneously, platelets aggregate to the injured site and 
initiate the formation of a primary clot allowing for continued hemostasis. Platelets 
release chemokines, epidermal growth factor (EGF), fibronectin, fibrinogen, histamine, 
platelet-derived growth factor (PDGF), serotonin, and von Willebrand factor, which 
modulate cell behavior to promote healing. 94 Once coagulation is established, neutrophils 
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remove cellular debris and inflammation manifests resulting in the production of 
chemokines and growth factors imperative for tissue repair. Macrophages, which are 
considered a prime source of growth factors including vascular endothelial growth factor 
(VEGF), platelet derived growth factor (PDGF), and transforming growth factor-beta 
(TGF-P),8 then replace neutrophils during the proliferative phase. New blood vessels and 
collagen are laid down in the wound bed during this stage of wound healing. 93 Studies 
indicate that diminished production of VEGF and decreased angiogenesis are thought to 
contribute to impaired tissue repair in diabetic patients. 7 The final steps of wound 
healing involve fibroblasts, which begin the deposition of collagen during the 
proliferative phase and complete scar formation during the final remodeling stage. 
Researchers have identified that defects in the inflammatory phase of healing directly 
cause failure in the subsequent fibroblast growth and collagen synthesis. 6 Decreased 
fibroblast growth and collagen deposition contribute to impaired wound healing. 
Although this remains a major complication in wound healing, many factors exist that 
also play a role in decreased healing seen in diabetics. 
D. Fibroblast Structure, Function and Effect on Diabetes 
A fibroblast is a cell that constitutes the ground substance of connective tissue, has a 
branched cytoplasm surrounding the nucleus, and functions to deposit collagen during 
scar formation. These cells, which are found in all connective tissues, synthesize and 
secrete extracellular matrix proteins. 17 Fibroblast cultures from patients with diabetes 
mellitus show diminished proliferation, abnormalities in protein synthesis and altered 
morphology. 12 Since fibroblasts are central to extracellular matrix deposition and 
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remodeling, any impediments to fibroblast formation will result in impaired wound 
healing.9 Studies indicate that fibroblasts also secrete enzymes known as matrix 
metalloproteases (MMPs ), which aid in remodeling through degradation of the existing 
extracellular matrices in preparation for new collagen deposition. Diabetic fibroblasts 
have been shown to produce significantly higher levels of pro-MMP-2 and pro-MMP-3 
than that of the nondiabetic fibroblasts; however, the higher levels of MMP-2 and -3 
produced by diabetic fibroblasts may result in excessive degradation and destruction of 
chemotactic fragments, thus delaying cell recruitment and wound healing. 14 Therefore, it 
is imperative that we understand that although diabetics have shown decreased fibroblast 
formation and function, the production of MMPs have been shown to be increased in the 
same population. Matrix metalloproteases are essential in remodeling, but excess levels 
of these enzymes may also lead to diminished wound healing in the diabetic patient. 
Since fibroblasts play such an essential role in matrix deposition, they present as a well 
established system for in vitro analysis of fibroblast growth, migration and collagen 
b 1. . d h 1. 1s 19 20 21 meta o ism m woun ea mg. ' ' ' Therefore, we have chosen adult dermal 
fibroblasts as the cell of interest in our research modality. 
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Advanced Glycosylation End Products (AGEs) 
A. Formation of advanced glycosylation end products 
Advanced glycosylation end products, which are formed by the non-enzymatic "Maillard 
reaction" of glucose and other reducing sugars with amino groups on proteins, nucleic 
acids and lipids, are generated in increased amounts during chronic hyperglycemia and 
are believed to contribute significantly to the vascular disease seen in diabetes mellitus as 
well as the pathogeneses of aging. 23'26 AG Es form at a constant but slow rate in the 
normal body, starting in early embryonic development, and accumulate with time; 
however, their formation is markedly accelerated in diabetes because of the increased 
availability of glucose. 27 These glycation modifications occur preferentially on lysine 
and arginine amino acids, although they can occur on free amine containing lipids and 
DNA.29 The definition of glycation comprises a series of reactions that includes the 
binding of the acyclic form of a sugar to specific amino acids on a protein to form a 
Schiff base, rearrangement of the Schiff base to form an Amadori product (so-called early 
products), and cross-linking and subsequent degradation of proteins to form advanced 
glycation end-products. 24 Non-oxidative rearrangement of Amadori products can result 
in the formation of intermediate products collectively known as a-oxoaldehydes. These 
products include 3-deoxyglucasone (3-DG), glyoxyl and methylglyoxyl (MGO), which 
can produce AGEs such as pyrraline, CML and CEL, respectively, via the polyl pathway. 
Methylglyoxyl has been implicated as one of the mechanisms that leads to hyperglycemia 
induced damage in diabetes by induction of oxidative stress and cellular apoptosis. 90-92 In 
addition to those endogenously formed, AGEs can also be introduced into the body from 
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exogenous sources such as tobacco smoke and dietary intake.27 Although exogenous 
AGEs and their possible detrimental affects deserve further investigation, current diabetic 
research appears to focus on endogenous AGEs since numerous systemic complications 
have been documented to be associated with these products. Various AGEs do exist and 
they differ slightly in structure depending on the protein cross-link. The most common 
documented AGE structure is that of N-Carboxymethyllysine (CML), and therefore 
represents the reason for using CML as a cell stimulant during this in vitro study.92•128 
B. Advanced glycosylation end product receptors 
Activation in response to advanced glycosylation end products results from the binding of 
the AGE to its receptor. Despite the apparent focus among researchers to identify RAGE 
(receptor for advanced glycosylation end product) as the central receptor for AGEs, many 
different receptors exist. Several AGE binding proteins have been identified, including 
OST-48 (AGE-Rl), 80K-H (AGE-R2), galectin-3 (AGE-R3), the AGE receptor complex 
(AGE-RC), RAGE, the macrophage scavenger receptor A (MSR-A), particularly Type II, 
lactoferrin, and lysozyme. 28 '29 These molecules have been documented to bind to AGEs 
in vivo, but data suggesting that they act as AGE receptors in vitro is limited. 
Researchers have minimal knowledge of the exact role with which all of these receptors 
have in tissue destruction, however studies do indicate that activation via the galectin-3 
receptor functions as a protective mechanism by degrading advanced glycosylated end 
products and thus eliminating the deleterious effects of these products. In contrast, 
RAGE, which is a multiligand member of the immunoglobulin superfamily of cell 
surface molecules, appears to promote target tissue damage through the induction of 
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oxidative stress. 28•33 RAGE is present at low levels in a range of cell types such as 
endothelium, monocytes, vascular smooth muscle , mesangium and neurons; in diabetes, 
however, the expression of RAGE is enhanced , and strikingly co-localizes with that of 
AGE.32 Oxidative stress induced by AGE binding to RAGE causes activation of signal 
transduction cascades, which then results in increased NF- 1.':B activation and subsequent 
increased transcription of inflammatory genes .36 AGE-R2 , which is also believed to 
promote tissue damage , has not been studied to the degree that RAGE has and therefore , 
little is known about the mechanism by which AGE-R2 causes destruction . On the other 
hand, MSR-A and AGE-Rl have been implicated as receptors that sequester AGEs. 
Over-expression of AGE-Rl enhances AGE binding and degradation, inhibits RAGE-
mediated RAS-MAPK-NF- nB-MCPl activation and thus may represent a unique 
candidate for AGE-defense element intended for tissue protection against AGE toxicity. 30 
Studies conducted by researchers in Japan indicate that MSR-A plays a major role as the 
AGE-receptor in endocytic uptake of AGE-proteins. 31 Enhanced research, specific to 
identifying the role of these receptors , will help us to have a greater understanding of the 
pathophysiology of diabetes and the contribution with which AGEs have in many 
systemic complications related to diabetes. 
C. Diabetic complications implicated by A GEs 
Advanced glycosylation end products have been implicated in multiorgan diabetic 
complications including atherosclerosis, nephropathy, neuropathy, retinopathy, and 
decreased wound healing. Each condition results from the multipotent bioactivities of 
AGEs through their receptors as well as the functional and structural derangement of the 
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AGE-bearing proteins. 37 This heterogeneous group of compounds can cause a number of 
adverse cellular events , including reduction of enzymatic activity, damage to nucleic 
acids, cross-linking and impaired degradation of proteins , and induction of cytotoxic 
pathways . 38 Micro and macro-angiopathies occur as a result of these events and may 
manifest into end organ failures. For instance , diabetics are at high risk of vascular 
plaque formation, which may lead to coronary artery disease , cerebral vascular accidents, 
and ultimately death. 126 Studies show that increased AGE accumulation in the diabetic 
vascular tissues has been associated with changes in the endothelial cell , macrophage , and 
smooth muscle cell function. In addition, AGEs can modify LDL cholesterol in such a 
way that it tends to become easily oxidized and deposited within vessel walls , causing 
streak formation and, in time, atheroma. 26 Such factors are believed to contribute to the 
reason that the number one cause of death among diabetics is cardiovascular disease. 
Other diabetic complications can also have devastating end results. According to the 
CDC, the number one cause of end stage renal disease (ESRD) in the United States is 
diabetic nephropathy, which does not affect all diabetics. 127 However , studies show that 
the diabetic population that is affected by nephropathy also has a higher risk of 
cardiovascular disease. Diabetic neuropathies can affect many organ systems and 
manifest in many different ways, while retinopathy has been shown to be the number one 
cause of blindness among this population. 126 The deleterious effects implicated in these 
complications are an indication of the importance of researching advanced glycosylation 
end products and their affects on specific MAPK pathways. 
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D. Advanced Glycosylated End Products and Wound Healing 
As previously discussed, advanced glycosylated end products result in the formation of 
covalent bonds that adversely affect proteins such as collagen. Chronic accumulation of 
AG Es induce these pathological cross links, which lead to increased stiffness of the 
protein matrix, disrupted function and increased resistance to removal by proteolytic 
means.
92 In the wound, RAGE-bearing mononuclear phagocytes(MPs) and other cellular 
effector cells, such as lymphocytes, endothelial cells, and fibroblasts, interact with AGEs 
and EN-RAGEs (the latter released from invading inflammatory cells) in a sustained 
manner.
71 Once at the injury site, cytokines and MMPs are released, which thereby 
further activate the inflammatory process. Prolonged existence of MPs within the fibrin 
clot will lead to persistent activation of RAG Es and therefore hinder tissue remodeling. 
Goova et. al. describes this process in Figure 1. 
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Figure 1. Blockade of RAGE restores effective wound healing in db+/db+ mice. In diabetes , influx of 
inflammatory cells such as PMNs and MPs into wound foci is markedly delayed. RAGE-bearing 
inflammatory cells are trapped by AGEs within the dennis (arrows; red segments). Once they gain access 
to the wound (arrows ; yellow ⇒ green segments) , however , inflammatory cells such as MPs , along with 
other RAGE-bearing effector cells (such as fibroblasts and endothelial cells) , interact with AGEs and EN-
RAGEs . Activation of RAGE initiates a cascade of cellular activation , typified by generation of cytokines 
and MMPs (green arrows). Delayed egress of inflammatory cells portends ongoing stimulation of RAGE , 
sustained inflammation , and failure ofreparative /remodeling processes . We speculate that blockade of 
RAGE both hastens and appropriately limits the inflammatory phase of wound healing in diabetes , thereby 
promoting closure. 7 1 
Advanced Glycosylation End Product Signaling 
A. Mitogen Activated Protein Kinase (MAPK) Pathway 
The mitogen activated protein kinase pathway is a paradigm for signal transduction , as it 
occupies a central role in key cellular processes including cell differentiation , cell 
survival and cellular adaptation to chemical and physical stress.95-98· ' 00 The term 'MAPK 
pathway' refers to a module of three serine/threonine protein kinases , which are activated 
11 
by sequentially phosphorylating each other in response to a diverse range of stimuli , such 
as cytokines , growth factors , neurotransmitters , cellular stress and cell adherence .96 
Specifically, MAPKs are phosphorylated and activated by MAPK-kinases (MAPKKs) , 
which in turn are phosphorylated and activated by MAPKK-kinases (MAPKKKs); the 
MAPKKKs are activated by interaction with GTPases and/or other protein kinases , which 
connects the MAPK module to cell surface receptors or external stimuli. 10° Figure 2 
demonstrates the overall sequence of events involved in the MAPK pathway. 
MAP KKK 
(MEK112) MAP KK 
l 
~RK112 ) MAPK 
l 
€}) ~ ~ 
l 
(Transciptional regulation) 
Summary of Map kinase pathway 
Figure 2. The growth factor ligand binds to its trans-membrane receptor and activates 
tyrosine kinases inherent in the receptor molecule (RTPK). A series of proteinZDprotein 
complexes form involving Shc(Ras) , GRB-2 , and SOS. Subsequent to this, GDP-Ras is 
converted to GTP-Ras , which activates Raf, MEK and then MAP kinase. Map kinases 
phosphorylate a number of transcription factors including TCFs. 101 
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B. Jun-N terminal kinase (JNK) Pathway 
Jun-N terminal kinases, also known as stress activated protein kinases (SAPKs), are 
members of the mitogen activated protein kinase (MAPK) superfamily, which undergo 
activation by stress induction and are believed to play a significant role in apoptosis. 
Three genes exist including JNKl, JNK.2, and JNK3. JNK kinase activity can be 
activated by various stimuli, including pro-inflammatory cytokines TNF-alpha (tumor 
necrosis factor-alpha) and interleukin 1 (IL-1 ), lymphocyte co-stimulatory receptors 
(CD28 and CD40), Ras, DNA damaging chemicals, radiation, GPCR and Fas 
signalling. 39 The sequence of events leading to JNK activation involves upstream 
cytokine receptors, adaptor proteins, GTPases, and mitogen activated protein kinases. 
Although the MAPK.Ks, MKK4 and MKK7, have been established as specific activators 
of JNK, more than a dozen additional MAPKKKs are also known to activate this 
pathway.40 JNK enters the nucleus and phosphorylates nuclear substrates including c-
Jun, ATF-2, and Elk-1 and non-nuclear substrates such as Bcl-2 family members. 41•42 
This activation subsequently results in transcription signaling and therefore regulation of 
processes including gene expression, metabolism, differentiation and apoptosis. 
Previous studies indicate that the role that JNK plays in apoptosis is complicated and may 
vary depending on the experimental cell type. Some studies label JNK as pro-apoptotic, 
while others indicate an anti-apoptotic effect. Understanding the role JNK has in the 
apoptosis pathway may help identify therapeutic approaches for treating type II diabetic 
complications. Figure 3 depicts the JNK signaling pathway. 
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Figure 3. JNK belongs to the mitogen-activated protein kinase (MAPK) superfamily. JNK plays a 
crucial role in inflammatory responses, stress responses , cell proliferation , apoptosis , and tumorigenesis. 
JNK kinase activity can be activated by various stimuli , including the proinflammatory cytokines (TNF-
alpha and interleukin-I) , lymphocyte costimulatory receptors (CD28 and CD40), DNA-damaging 
chemicals, radiation , and Fas signaling. Results from the JNK knockout mice indicate that JNK is involved 
in apoptosis induction and T helper cell differentiation. 129 
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C. p38 Pathway 
The P38 family is a serine/threonine protein kinase that belongs to the MAPK 
superfamily and exists in four forms including alpha, beta, gamma and delta. P38s 
resemble JNKs in that they are stress-activated kinases. In almost all instances, the same 
stimuli that recruit the JNKs/SAPKs also recruit the p38s including osmotic shock, UV 
irradiation, heat shock, oxidative stress, inhibition of protein synthesis, stimulation of Fas 
and proinflammatory cytokines such as tumor necrosis factor a (TNFa) and interleukin-I 
(IL-1).44•45 As seen in the JNK pathway, the sequence of events in the p38 pathway is 
complex and involves many upstream activating kinases. Apoptosis-signal regulating 
kinase-1 (ASKl) has been found to be highly involved in the activation of the p38 
MAPK-c-Jun pathway during apoptosis. 45 ASKl activates MKK4/7 signaling cascades, 
which then activates both MKK3 and MKK6. Several studies have suggested that MKK4 
is not a physiologic activator of p38, but that MKK3 has been shown to preferentially 
activate p38a . and p38P while MKK6 strongly activates all known p38 isoforms. 43•46 
Once inside the nucleus, p38s phosphorylate transcription factors (Max, CREB, MEF2, 
ATFl/2, c-Myc, STAT3, and ELKl) and activate other kinases (MNKl/2, MAPKAPK). 
P38s have been implicated in processes such as apoptosis, transcriptional regulation, 
cytoskeletal reorganization, inflammatory cytokine production, and even cell survival in 
cell types such as cardiac myocytes. 46'47•48 Figure 4 demonstrates the p38 pathway. 
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y radiation, AnllOlllycln 
Figure 4. The SAPK2/p38 pathway is implicated in conveying signals that trigger the induction of a 
variety of responses in many different types of cells. In particular, the inflammatory response is tightly 
associated with the activation of SAPK2 /p3 8. It leads to induction of proinflamatory cytokines such as 
TNF-a and interleukins by macrophages , induction of adhesive molecules (E-selectin) on endothelial cells , 
induction of the respiratory burst , and up-regulation of ~2 integrins in neutrophils. SAPK2/p38 is also 
importantly involved in regulating apoptosis to oxidative stress, chemotherapeutic agents and heat 
shock. 130, 132 
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D. ERK pathway 
Despite also being a serine/threonine kinase in the MAPK superfamily, the extracellular 
signal-regulated kinase (ERK) pathway differs from both the JNK and p38 pathways in 
that it is not stress activated . This pathway, also known as the p42/p44 MAPK pathway, 
is activated by a wide variety of mitogenic stimuli which interact with structurally 
distinct receptors and thus represents a convergence point for most, if not all, mitogenic 
signaling pathways. 50 The receptors associated with ERK activation include receptor 
tyrosine kinases (RTKs), G-protein coupled receptors (GPCRs), integrins and ion 
channels. Although many options exist for activating ERKl/2, the most commonly 
documented sequence of events involves the Ras-Raf-MEK-Erk signaling cascade. This 
pathway begins with the binding of an epidermal growth factor (EGF) to a receptor 
tyrosine kinase. Consequently, the GRB2-SOS complex attaches to phosphotyrosines 
and thus stimulates the exchange of energy via the conversion of GDP into GTP. The G-
protein Ras becomes activated and recruits Raf-1 from the cytosol, which then follows 
through a multi-step process that leads to phosphorylation and activation of MEKl/2. 
Significant ERK activation requires phosphorylation at both tyrosine and threonine 
residues with Tyr phosphorylation preceding that of Thr. 51 Once this occurs, MEK 1/2 
phosphorylates and activates ERKl/2, which has substrates in both the cytosol and the 
nucleus. Transcription factors affected by ERK in the nucleus include Elk-1, MSK 1/2, 
STAT 1/3, and c-Myc. This ERK cascade has been shown to function in cellular 
proliferation, differentiation, and survival, and its inappropriate activation is a common 
occurrence in human cancers. 49 Figure 5 represents the ERK pathway. 
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Figure 5. The binding of epidermal growth factor (EGF) induces receptor autophosphorylation on 
tyrosine residues leading to activation of the small G-protein Ras by stimulating the exchange of guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP) . This exchange elicits a conformational change in 
Ras, resulting in Raf-1. Activated Raf-1 phosphorylates and activates MEK , which in turn phosphorylates 
and activates extracellular-signal-regulated kinase (ERK) . Activated ERK has many substrates in the 
cytosol . ERK can enter the nucleus to control gene expression by phosphorylating transcription factors 
such as Elk-1 and other Ets-family proteins. 131 
E. P/3-K & AKTIPKB Pathway 
AKT, also known as protein kinase B (PKB), is another serine/threonine kinase that is a 
critical enzyme in several signal transduction pathways involved in cell proliferation, 
apoptosis, angiogenesis , glycogen metabolism control and gene transcription. 54'55 The 
pathway begins with either the binding of a growth factor to a tyrosine kinase receptor in 
the cell membrane or with cytokine stimulation. Autophosphorylation on tyrosine 
18 
residues leads to the recruitment of PBK to the membrane, which phosphorylates 
phosphoinositol lipids on the 03 position of the inositol ring generating Ptdlns-3-
phosphates (PIP3). 53 Activation of phosphoinositide 3 kinase (PB-K), which is upstream 
of AKT, results in phosphorylation of PIP3 into PIP2. Akt, a key downstream effector of 
PBK, is then recruited to the plasma membrane by these lipid products, phosphorylated, 
and consequently activated by PDK. 53•56 In response, Akt phosphorylates multiple 
proteins on serine and threonine residues and carries out its role as a key regulator of a 
variety of critical cell functions including glucose metabolism, cell proliferation and 
survival. 53 Research has helped to identify the role with which Akt signaling has in 
diseases such as cancer, Alzheimer's and diabetes. Previous studies indicate that defects 
in Akt signaling have a role in the development of insulin resistance and that both 
decreases and increases in Akt activity exist in diabetes, depending on the type of 
diabetes and the cell type studied. 58 Further research involving this pathway may help 
researchers to identify the role of this pathway in apoptosis and diabetes and thus 
subsequent treatment modalities of diabetes. 
F. Other AGE Pathways 
Advanced glycosylated end products play a role in many signaling pathways as is evident 
by those mentioned above. Along with the Ras/MAPK pathways, studies show that 
AGEs also activate the JAK/ST AT, nitric oxide synthase, AP-1, and NF-,.:B pathways. 102-
108 An inhibition study performed by Huang et al. demonstrated that the activation of 
JAK2, STATl and STAT3 was associated with the AGE-induced proliferation of the 
NRK-49F cells, which is a cell line of the renal interstitial fibroblast; this is important 
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because the proliferation of interstitial fibroblasts might contribute to renal fibrosis and 
subsequently diabetic nephropathy. 105 Diaglycerol (DAG) and PKC are critical 
intracellular signaling molecules that can regulate many vascular functions, and can 
indirectly be activated by reactive oxygen intermediates (RO Is) and AGEs. 112 PKC 
activation increases the expression of transforming growth factor-b (TGF-b ), which 
is thought to lead to the thickening of capillary basement membrane, one of early 
structural abnormalities observed in almost all tissues in diabetes. 113 Sumi et. al. 
observed that AGEs induce iNOS and HO-1 expression in RAW 264.7 cells (a 
macrophage cell line) via JNK and p38 MAPK phosphorylation, and therefore is believed 
to have a role in diabetic atherosclerosis. 108 A study by Nakamura et. al found that DNA 
binding activity for AP-1 site was significantly activated in the cells treated with AGEs-
BSA, which suggests that activation of AP-1 by increased intracellular oxidative stress 
may be involved in the augmented aldose reductase expression elicited by AGEs. 109 
Under hyperglycemic conditions, elevated expression of aldose reductase was reported in 
a variety of tissues including the target organs of diabetic complications. 109- 111 Finally, 
NF-KB activation via AGEs has been shown to occur in animal livers and mononuclear 
phagocytes. 114 NF-kB is a critical factor transducing a variety of inflammatory and pro-
or anti-apoptotic signals in the cell, depending on the time course, site, and chronicity of 
stimulus, and therefore has a significant role in diabetes associated end organ 
1. · 115 comp 1catlons. 
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Cellular death via apoptosis 
A. Apoptosis pathway 
Cellular death, also known as cellular "suicide", is an essential mechanism of all 
multicellular organisms. This process is required in order to provide an environment for 
appropriate development and to protect organisms from harmful or damaged cells. 
Failure to invoke appropriate cell death can result in cancer or autoimmunity, whereas 
increased programmed cell death (PCD) can lead to degenerative processes such as 
immunodeficiency and neurodegenerative disease. 59 Apoptosis, or programmed cell 
death, is a process where-in cells that are no longer needed or that will be detrimental to 
an organism or tissue are disposed of in a neat and orderly manner; this prevents the 
development of an inflammatory response, which is often associated with necrotic cell 
death. 60 In necrosis, cell swelling and subsequent cell rupturing can cause the 
intracellular contents that have been released to cause damage to surrounding cells 
resulting in the process of inflammation. However, apoptotic cells present much 
differently than cells undergoing necrosis or autophagocytosis and do not cause an 
inflammatory response. The morphological characterizations associated with apoptosis 
are chromatin condensation, cell shrinkage, nuclear and cytoplasmic fragmentation, and 
formation of membrane-bound apoptotic bodies that will undergo phagocytosis. 62 Cell 
changes consistent with programmed cellular death occur as cells submit to either the 
intrinsic or extrinsic apoptosis pathways. While the intrinsic apoptosis pathway begins 
when an injury occurs within the cell, the extrinsic pathway begins outside a cell, when 
conditions in the extracellular environment determine that a cell must die. 60 The 
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extrinsic pathway originates when factors such as tumor necrosis factor (TNF) or Fas 
ligand bind to their respective cell death receptors which are present on the cell 
membrane. This leads to the activation of caspases, which are members of the cysteine 
protease family and are well documented to be responsible for the morphological changes 
sustained by cells undergoing apoptosis. The three classes of caspases exist. The 
signalling caspases are involved in initiating the cell death process and maintaining the 
regulatory elements within it, while the effector caspases are essential for the initiation 
and execution of apoptosis. 133 The inflammatory caspases are involved in the processing 
and maturation of the inflammatory cytokines IL- lf3 and IL-18. 134 Caspases selectively 
cleave a restricted set of target proteins, most commonly resulting in inactivation of these 
proteins; however, caspases can also activate proteins, either directly or indirectly. 63 As a 
result of external stimuli, the "initiating" caspases 8 and 10 trigger the sequence of events 
involved in the extrinsic apoptosis pathway. In contrast, intracellular DNA damage and 
endoplasmic reticulum (ER) stress initiate the intrinsic apoptosis pathway. While ER 
stress directly activates caspase 12, the events involved in DNA damage are much more 
complex. In a healthy cell, the outer membranes of its mitochondria express the protein 
Bcl-2 on their surface which is bound to a molecule of the protein apoptotic protease 
activating factor-1 (Apaf-1). 62 Internal damage, which can occur as a result of reactive 
oxygen species, causes the Apaf-1 to be released from the Bcl-2. Bax, a protein that 
enters the mitochondrial membrane, ultimately causes the release of cytochrome C from 
the mitochondria. Cytochrome C binds to Apaf-1 and this complex adheres to caspase 9, 
which is then activated. Both pathways converge at caspases 3, 6, and 7, which have 
been implicated in the final destruction of cells and their proteins during cellular death. 
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The apoptosis pathway is a complex process, which involves many upstream proteins, 
kinases, transcription factors and caspases. It continues to be a focus in different areas of 
research since it has been attributed to many serious diseases including carcinoma, 
Alzheimer's, ALS, Parkinson's, HIV, and diabetes. 
B. A GE stimulation of the apoptosis pathway 
Advanced glycosylated end products have been documented to have a significant role in 
apoptosis. 71' 135 Although AGEs are pro-apoptotic for cultured retinal pericytes, corneal 
endothelial cells, neuronal cells, and renal mesangial cells, the exact mechanisms by 
which AGEs lead to apoptosis are not well understood. 64 The most recognized 
hypothesis among researchers is the notion that AGE induced apoptosis originates from 
the production of reactive oxygen species (ROS). AG Es have been documented to 
generate ROS, which induce cellular dysfunctions that can interfere with gene expression 
of peptides and cytokines involved in the regulation of cell proliferation, and therefore 
can mediate a signal for apoptotic cell death. 65-67 Since these advanced glycosylated end 
products are a consequence of chronic hyperglycemic states commonly seen among 
diabetics, cellular death pathways are likely to have a key role in initiating complications 
associated with this disease. 
C. AGE Signaling Apoptosis in Various Cell Types 
Research supports the role of MAP kinase pathways in various AGE induced apoptotic 
events, which continues to be a key component in diabetic complications. Macrovascular 
disease remains the major cause of mortality in the diabetic patient population, and thus 
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has been extensively studied. 116- 119 Hall et al. discovered that the vasculopathic effect of 
diabetes is associated with the inhibition of VSMC (vascular smooth muscle cell) 
apoptosis in vivo via the activation of PKC pathways, which links perturbations in 
cellular glucose metabolism to the regulation of VSMC fate. 119 In addition, AGE may be 
involved in the atherosclerosis processes by inducing dendritic cell maturation and 
increasing RAGE expressions, which were mediated by JNK signaling pathways in a 
study by Ge et al. 120 Hyperglycemia-induced activation of PKC-ijn appears to cause 
reduced proliferation and survival in vascular endothelial cells by blocking downstream 
insulin signaling through PI3k-Akt pathways, which is of great clinical relevance because 
restoration of insulin signaling is a major therapeutic intervention being tested in current 
clinical trials. 123 As previously discussed, nephropathy remains the leading cause of end 
stage renal disease in the United States. Yamigishi et al. demonstrated that various types 
of AGE increased p53 accumulation in mesangial cells, and therefore concluded that 
since p53 has been reported to promote programmed cell death through Bax protein 
expression in response to a number of stress signals. AGE might induce apoptotic cell 
death in mesangial cells through p53-dependent Bax expression and reactive oxygen 
species. 124 We have also discussed the deleterious effects of retinopathy on the diabetic 
population. Early loss of pericytes in retinal microvessels is considered to strongly 
contribute to retinopathy. 121 Denis et al. discovered that oxidative stress has a critical 
role in AGE-induced apoptosis of pericytes, which seems to act upstream of 
DAG/ceramide production and seems common to the two pathways leading to pericyte 
apoptosis induced by AGE. 121 Studies have also demonstrated the effect of AGEs and 
apoptotic signaling pathways on bone formation. Alikhani et al. showed that CML-
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collagen stimulated both p38 and JNK activity in osteoblasts and inactivation of both 
with inhibitors significantly reduced apoptosis, which indicates a pro-apoptotic pathway 
involving MAP kinase signaling and an anti-apoptotic pathway involving NF-KB. 122 As 
we can see, AGE signaling apoptotic pathways have a significant role in diabetic 
complications, and therefore the goal of the present study was to determine the role with 
which advanced glycosylated end product signaling pathways have in fibroblast apoptosis 
and their effects on the generation of diabetes mellitus associated complications. Once 
this role is established, therapeutic interventions focusing on the role of these pathways in 
diabetic complications can be further researched at an advanced level. 
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METHODS AND MATERIALS 
Cell Culture 
• Cell culture hood 
• NHDF-Adult cryopreserved fibroblasts (purchased from Cambrex) 
• FGM 2 Medium (Cambrex) 
• 25 and 75 cm3 cell culture (canted neck-plug seal cap) flasks 
• Microscope 
• 15mL and 50mL centrifuge tubes 
• Ependorff tubes 
• Pipettes, pipette tips, and Pasteur tips 
• 75% Denatured Ethyl Alcohol 
• Alcohol wipes 
• Hepes Buffered Saline Solution - 30mM (Cambrex) 
• Trypsin/EDT A Solution (Cambrex) 
• Trypsin Neutralizing Solution (Cambrex) 
• Centrifuge 
• 12-well cell culture plates 
• Cell Death Detection Elisa PLUS kit (Roche Applied Science) 
• Plate shaker 
• Wavelength detector/plate reader 
• P38 Elisa Assay 
A. Cell Culture Maintenance and Passaging 
Primary human adult dermal fibroblasts (NHDF-adult cryopreserved) were purchased 
from Cambrex (Walkersville, MD) and maintained in Dulbecco's Modified Eagle's 
Medium (Cambrex Company) supplemented with 10% fetal bovine serum, Gentamicin 
(l00µg/ml) and Amphotericin B (l00ng/ml). Before and after use, the cell culture hood 
was wiped down with 75% denatured ethyl alcohol to help avoid infection. Cell media 
was changed every other day and stored in an incubator at 3 7°C in a humidified 
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atmosphere of 5% CO2 for proper nutrition and growth. Adult dermal fibroblasts were 
initially cultured in 25cm 3 cell culture flasks until sufficient fibroblasts existed to allow 
for passaging into 75cm3 flasks or 12-well plates in preparation for experimentation 
(about 90% confluency). 
The number of passages was recorded so as not to exceed the recommended maximum of 
15 times. Each passage began with removal of the existing growth medium via suction 
with a sterilized Pasteur tip. To remove serum, cells were washed with Hepes Buffered 
Saline Solution according to the manufacturers' instructions. After two minutes, the 
Hepes solution was withdrawn and fibroblasts were then incubated at room temperature 
with a sterile Trypsin/EDT A solution containing .05% trypsin and .02% EDT A. Cells 
were monitored microscopically to ensure rounding up of cells and subsequent 
detachment from the flask. Once the cells were at least 95% released, Trypsin 
Neutralizing Solution (TNS) purchased from Cambrex was added. The Trypsin/TNS 
solution was placed in a 15mL tube and centrifuged at 1000 RPM at 4°C for 5 minutes to 
form a "cotton pellet". The supernatant solution was withdrawn with the Pasteur pipette, 
while avoiding removal of the centrifuged cells. Warmed medium was added to 
redistribute the fibroblasts and then cells were divided evenly into 75cm 3 flasks or 12-
well plates in preparation for experimentation. 
KINEXUS study 
Five 75cm3 flasks were prepared for protein extraction experimentation. Adult dermal 
fibroblasts were grown to about 85% confluency in each flask. Medium was changed to 
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serum free medium prior to experimentation. On the day of experimentation, one flask 
remained untreated as a control group. Two flasks were treated with .2mg/mL of 
unmodified collagen and protein extraction was done 45 minutes and 3 hours after 
inoculation. The remaining two flasks were treated with .2mg/mL of CML-collagen 
(modified collagen) and protein extracted at two time points: 45 minutes and 3 hours. A 
laboratory technician used a protein extraction protocol to prepare cells for transportation 
to the KINEXUS Company for western blot analysis. Eighteen kinases were evaluated 
for phosphorylation activity after advanced glycosylated end product stimulation. The 
experiment was repeated in the same fashion to confirm results. The results of this 
experiment were used to plan the experimental design of this study. 
P38 Elisa Assay 
To confirm the significant increase in p38 phosphorylation seen in the first Kinexus 
study, fibroblasts were stimulated with AGE and protein extraction was performed using 
the passaging technique previously discussed. Extraction was performed at 5 minutes 
and 20 minutes. A p38 Elisa assay, purchased from EMO Biosciences/Calbiochem (San 
Diego, CA), was used to identify the amount of phosphorylation that occurred when 
fibroblasts were stimulated with AGE. The assay was performed according to the 
manufacturers' protocol. 
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Experimental preparation 
A. CML-collagen preparation 
As previously discussed, CML is the most common advanced glycosylated end product 
seen in diabetics, and therefore CML was used in this study as the stimulant. AGE was 
generously provided by Dr. Trackman's laboratory based on the following protocol: 
CML-collagen was prepared by chemical modification of acid soluble bovine skin 
collagen (Sigma). Briefly, 50 mg of collagen was dissolved in 25 ml lmM HCl freshly 
made in sterile water and incubated at 3 7°C with occasional mixing. Sterile PBS (25 ml) 
was added, followed by sodium cyanoborohydride ( 1.42 g) and glyoxylic acid (0. 715 g). 
Control collagen was prepared at the same time, except that no glyoxylic acid was added. 
All samples were then incubated at 37 °C for 24 hours. AGE, collagen, and control 
collagen were then exhaustively dialyzed against distilled water. In dose response 
experiments where higher concentrations of CML-collagen were used, AGE and control 
collagen were dialyzed against PBS. Both CML-collagen and control collagen were 
soluble at the concentrations stored and tested. In total, 3 - 8% of lysine residues in 
CML-collagen were converted to CML, as determined by the TNBS 
(trinitrobenzenesulfonic acid) assay. The percent modification of collagen that we have 
generated is ten fold less than the amount used in a recent report to assess CML binding 
and activation of NFkB and only a small amount higher than that reported for the skin of 
aged or diabetic individuals. CML-collagen was highly reactive on Western blots with 
anti-CML monoclonal antibody 6D 12 (Wako, Richmond,VA) , whereas control collagen 
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was not reactive. The amount of endotoxin contamination was measured by Pyrochrome 
Limulus Amebocyte Lysate (LAL) assay ( Associates of Cape Cod, Inc, Woods Hole, 
MA) and found to be low, 0.094 + 0.01 ng/mg LPS in control collagen and0.087 + 0.01 
ng/mg LPS in CML-collagen. 65 
B. Kinase inhibitors 
Based on the results of a phosphorylation assay done in a previous study, kinases of 
interest were determined. The assay determined that certain target kinases were activated 
in response to advanced glycosylated end products, but the role with which they played in 
apoptosis was unknown. It was decided that the Akt, p38, ERK, and JNK kinases and 
their pathways should be researched to determine their involvement in apoptosis. To do 
this, inhibitors for each of these kinases were purchased after extensive on-line research 
of available products. The most highly selective inhibitor available was purchased as 
well as a second less highly selective inhibitor, if available. The following inhibitors 
were purchased from EMO Biosciences/Calbiochem (San Diego, CA): JNK inhibitor II 
(Anthra), JNK inhibitor I, SB203580 (p38 MAPK inhibitor), ML3403 (p38 MAPK 
inhibitor III), PD98059 (highly selective for MEK 1/2 and weakly selective for ERK 1/2, 
and Akt inhibitor IV. The highly selective Akt inhibitor, Triciribine (TCN), was 
purchased from Berry and Associates, Inc. (Dexter, MI). The PBK inhibitor, L Y294002, 
was purchased from LC Laboratories. (Woburn, MA). Inhibitors were received in 
powder form and were suspended in solution based on the manufacturers' 
recommendations. Articles referencing each of these products were used to determine 
the appropriate concentrations for cell stimulation. 135-40 
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Experiments 
A. Fibroblast stimulation 
Experiments were performed with the presence of a control group, a control-collagen 
group, and a CML-collagen group as references for the inhibitor groups. In all 
experiments, .2mg/mL of CML-collagen (modified collagen) and .2mg/mL of 
unmodified collagen were used. Cell medium was changed to serum free medium prior 
to experimentation. Assays were performed when the cultures reached 75% to 85% 
confluency. The fibroblasts were treated with inhibitor one hour prior to stimulation with 
CML. Apoptosis was then measured 24 hours after stimulation with CML by using the 
ELISA technique. Prior to using this technique, cell numbers were assessed to normalize 
apoptosis measurements. The Cell Death Detection ELISAPLUS kit is a photometric 
enzyme-immunoassay that determines qualitative and quantitative in vitro cytoplasmic 
histone-associated- DNA-fragments (mono-and oligonucleosomes) after induced cell 
death (Roche Applied Science, Indianapolis, IN). 
B. Apoptosis Assay 
For each apoptosis assay done, the following steps were used. Cells were placed in 
serum free media for 24 hours prior to treatment with AGE. After 24 hours of treatment, 
the medium was removed via suction with a sterilized Pasteur tip. For each flask or well, 
cells were washed with Hepes Balanced Saline Solution and removed after two minutes. 
Cells were inoculated with trypsin and monitored for detachment. Once at least 95% 
detached, TNS was added to neutralize the trypsin. This solution was placed in a l 5mL 
centrifuge tube and spun at 1000 RPM and 4 °C for 5 minutes. Each tube was checked to 
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see that a pellet had formed and then the supernatant solution was removed with a Pasteur 
tip, being very careful not to touch the pellet. Cells were then re-suspended in 200µL of 
lysis buffer provided in the cell death detection ELISA provided by Roche Applied 
Sciences. Cells were then transferred to Ependorff tubes using a pipette and allowed to 
incubate for 30 minutes at 15-25°C. While the lysis buffer was incubating, an 
immunoreagant solution was prepared depending on the number of samples to be tested. 
(Table 1) 
Table 1. Immunoreagant preparation 
# tests 10 20 40 50 100 
Incubation 720µL 1440µL 2880µL 3600µL 7200µL 
Buffer 
Anti-hi stone- 40µL 80µL 160µL 200µL 400µL 
biotin 
Anti-DNA- 40µL 80µL 160µL 200µL 400µL 
POD 
Immunoreagant 800µL 1600µL 3200µL 4000µL 8000µL 
Total amount 
After 30 minutes, the eppendorff tubes were centrifuged at 200 x g for 10 minutes. Tubes 
were removed from the centrifuge carefully to avoid disturbing the nucleosomes. From 
each eppendorff tube, 20µL was removed from the top of the supernatant being careful 
not to allow the pipette tip to penetrate the lower portion of the supernatant. The contents 
from each tube were then plated into the center of individual streptavidin coated wells 
provided in the apoptosis kit. Once all samples were plated, 80µL of immunoreagant 
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previously prepared were added to each well. The microplate was then covered with a 
foil provided in the ELISA kit and incubated on a microplate shaker at 300rpm for 2 
hours at l 5-25°C. During the 2-hour incubation, a 2,2'-azino-bis(3-ethylbenzthiazoline-
6-sulphonic acid) substrate solution (ABTS) was prepared using reagents provided by 
Roche Applied Sciences. (Table 2). 
Table 2. ABTS Substrate Preparation 
One tablet 5mL substrate buffer 
Two tablets l 0mL substrate buffer 
Three tablets l 5mL substrate buffer 
After two hours, the microplate plate was removed from the microplate shaker. Each 
well was rinsed 3 times with 250-300µL of incubation buffer provided by the apoptosis 
kit. The incubation buffer was removed and bubbles removed with suction tip, making 
sure to avoid touching the bottom of the well. 1 00µL of ABTS solution was added to 
each well with all lights off. Once all wells were incubated with ABTS, the microplate 
was covered with foil, lights were turned back on, and the microplate was placed on the 
shaker at 250 rpm until color development was sufficient. Once a green color was noted, 
the microplate plate was placed in a plate reader and steps followed according to the 
manufacturers' recommendations. The wavelength was measured with a primary filter 
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set at 405nm and a secondary filter of 492nm as suggested by the guidelines in the cell 
death detection ELISA kit. A printout was then obtained and recorded in a laboratory 
notebook. 
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RESULTS 
A. KINEXUS study 
In order to develop an experimental design , a protein extraction experiment was done 
using AGE/CML to stimulate cells and measure phosphorylation activity. In three 
separate experiments, fibroblasts were stimulated for 45 minutes and 3 hours with either 
CML or control-collagen. Samples were sent to KINEXUS and western blot analysis 
was done. No significant differences were noted between the 45-minute groups and the 
3-hour groups. The actual western blots provided by KINEXUS for all three experiments 
tested at 45 minutes are present in Figures 6-11. 
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Figure 6. This western blot represents kinase activity when fibroblasts were 
stimulated with CML for 45 minutes. The results are from the first Kinexus study. 
Lanes are labeled 1-19. 
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Figure 7. Represents western blot of kinase activity when fibroblasts were treated 
with CML for 45 minutes. This is the first CML sample of the second KINEXUS 
study. Lanes are labeled 1-19. 
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Figure 8. This western blot represents kinase activities when fibroblasts were 
stimulated with CML for 45 minutes. Lanes are labeled from 1-19. This represents 
the second sample of CML treated cells from the second KINEXUS study. 
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Figure 9. This western blot represents kinase activity when fibroblasts were 
stimulated with collagen for 45minutes. The results are from the first Kinexus 
study. Lanes are labeled 1-19. 
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Figure 10. This western blot represents the first sample of the collagen control 
performed during the second KINEXUS study. Lanes are labeled 1-19. 
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Figure 11. This western blot represents the second sample of collagen control 
treated fibroblasts performed in the second KINEXUS study. Lanes 1-19 are 
labeled. 
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The protein extraction experiment was later repeated to confirm results, and Table 3 
shows the mean fold change of each individual experiment. The first 3 columns represent 
the first KINEXUS experiment done. Table 4 represents the CML-collagen and collagen 
means and the standard errors for each. 
Gene Name CML #1 Collagen Fold Change CML #2 Collagen iFold Change CML #3 Collagen Fold Change i 
p38aMAPK 787 287 21%786352 1076 1144 o.94omm 1m 967 1368663633 
PKCa 8080 8819 0.91622)908 1m 7889 0.927217872 6396 8794 o.mmo12 
JNK (&\PK) 866 148 5.868405478 225 286 
JNK(SAPK) 2)7 827 81 1024267665 1021 lll 9.208217164 
ERKl 4034 326 12J9148972 4009 1882 2.129957589 4204 m4 1151B9679 
ERK2 %00 89 40.24227526 3435 977 1517055893 3795 557 6.817719%5 
IKKb 441 357 l.236928135 08 466 0.660100964 281 260 l.078107591 
IKKa 117 127 0.923445576 57 606 1.2488777) l 376 251 l.499761281 
MKK3/6 1297 1824 0.71097153 2)09 2096 l.101556589 2207 1649 1338719985 
MKK6 B6 203 0.670399757 186 178 1.04254943 268 158 l.694463359 
MEK2 human 3824 3618 1.05693816 6965 8091 0.860846478 7209 10340 0.697119436 
MEKl/2 226 149 1.51329534 518 564 0.917334953 m 836 0.614139255 
Table 3. The phosphorylation activity of 18 kinases was tested using 
The Western blot technique done by KINEXUS. All three studies are represented 
above: #1 = first blot (1st KINEXUS study), #2= second blot, #3= third blot (#2 and 
#3 are from the 2nd KINEXUS study). 
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Mean Fold Change T-test p value 
Gene Name Mean AGE Std Error AGE Mean Collagen Std. Error Collagen AGFJCollagen AGFJcollagen 
pmMAPK 1061.992418 155.0717 799.3861217 261.5224 1.328509951 0.435951093 
PKCa 7263.757139 487.3831 8500.784356 529.8663 0.854480814 0.097805771 
JNK(~K) 459.1270718 204.5025 147.6358697 NIA 'i;1 3.109861261 NIA 
JNK(SAPK) 694.9807451 236.0279 95.80204864 NIA 11 7 .254341165 
.. 
N'A i; ,: 
ERK! 4082.067 448 61.3325 1180.550263 456.2145 ;--;,.. 3.45776675 ,i 0.003228526 
ERK2 3610.066073 104.1665 540.9214731 256.7723 l 6.673918956 ~ 0.00037489 
IKKb 343.2360797 49.51 361.107 47 49 59.5712 0.950509484 0.829003686 
IKKa 416.5316381 86.0879 327. 670782 143.7052 1.270815972 0.7244669 
MKK3/6 1937.652713 557.1726 1856.25804 130.2007 1.043848792 0.826079828 
MKK6 196.2963485 66.6433 179.4782626 13.0325 1.09370542 0.699455424 
MEK2 human 5999.067395 1091.237 7349.647956 1977.901 0.816238741 0.581698162 
MEKl/2 419.0113902 96, 25 516.5321487 199.9835 0.81120099 0.682810119 
Table 4. This chart represents the mean AGE, mean collagen, Standard Error of 
AGE and of collagen, mean fold change of AGE compared to collagen, and T-test 
value of all three western blots. Some values were not obtained if all three values 
were not reported by KINEXUS. The yellow blocks represent mean fold changes 
above 2. The orange blocks represent significant change as provided by the T-test. 
The JNK T-test p value was not applicable, as some values were not obtained due to 
a faint band on the western blot. 
As previously discussed , 5 groups were tested in this protein extraction study. Two 
controls existed with the first being the group in which cells were not treated with 
anything. A collagen control group was necessary to rule out the role of collagen in 
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kinase phosphorylation, since the AGE used was a modified collagen. Flasks stimulated 
with AGE were measured at two time points ( one hour and three hour) for the first 
KINEXUS study and at one time point for the confirmation KINEXUS study (one hour). 
A calculation of the fold change was obtained by dividing the 1-hour AGE group by the 
1-hour collagen control group. The results from the first KINEXUS study indicated that 
the kinases p38 MAPK, JNK, ERK 1 and ERK 2 were highly phosphorylated in the 
presence of advanced glycosylated end products. Based on these results, these kinases 
were tested in the present study for their role in fibroblast apoptosis. AKT and PBK 
were not tested in the first KINEXUS study, but it was decided to test Akt and PBK as 
target kinases of interest in the inhibitor study. A second study was done using 
KINEXUS to confirm the results of the first western blot. Duplicate samples from the 
second protein extraction experiment were sent to KINEXUS so that two western blots 
could be obtained. In this study, p38 MAPK was not as highly phosphorylated as seen in 
the first KINEXUS study. 
The mean fold changes of all kinases studied in the inhibitor study are represented in the 
graph present in Figure 12. 
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Figure 12. Mean fold change was obtained by dividing the mean of AGE from all 
three western blots by the mean of collagen from all 3 western blots. An asterisk 
above the bar represents a significant fold change. 
Figure 12 represents a bar graph of the average amount of phosphorylation that occurred 
in all three western blots performed. As can be seen, ERKl/2 and JNK(SAPK) had 
significant fold changes when fibroblasts were stimulated with AGE. P38 and Akt did 
not have significant fold changes , despite having a significant increase in phosphorylation 
in the first western blot. 
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Figure 13. The above diagram shows the effect of AGE stimulation on 
phosphorylation of target kinases using the numeric values obtained from 
KINEXUS. AGE stimulation significantly increased phosphorylation of ERKl/2, 
JNK/SAPK, but showed no change with p38 when a mean fold change of all three 
KINEXUS studies was obtained. Some kinases were not tested in this study. 
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Figure 14. A p38 Elisa assay was performed to confirm the first Kinexus results 
that indicate that p38 is highly phosphorylated when stimulated with AGE. 
Fibroblasts were stimulated with AGE at 5 minutes and 20 minutes. Results 
indicate a high phosphorylation level of p38 when stimulated with AGE for 5 
minutes. Results are slightly inconsistent with the first Kinase study, which 
indicates high phosphorylation when fibroblasts were stimulated with AGE for 1 
hour. This graph indicates peak p38 phosphorylation at 5 minutes. 
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Figure 15. The Akt pathway as it relates to the KINEXUS study. Only one kinase 
was tested, which indicated no significant changes in phosphorylation when 
stimulated with AGE. 
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B. Inhibitor Study 
To test the role with which JNK, ERK, p38, Akt, and PI3K have in apoptosis, we utilized 
an in vitro study using primary adult dermal fibroblasts. Inhibitors were purchased and 
tested for each pathway listed. 
Akt/PI3K Pathway 
The first kinase to be studied in the inhibitor study was Akt. As previously discussed, 
this kinase was not tested in the initial KINEXUS study, but we were interested in 
investigating the role with which it had in fibroblast apoptosis. A second protein 
extraction experiment was later done to confirm the previous phosphorylation results of 
common genes of interest. Duplicate samples were sent to KINEXUS for analysis by 
performing two different Western blots. In this second study, Akt was tested along with 
a few other new kinases. Based on these blots, Akt did not show an increase in 
phosphorylation. However, the consideration to include Akt in the inhibitor study was 
originally based on the well-established role of Akt in cell survival as well as optical 
densitometry results obtained from a previous study performed in our laboratory. This 
study was performed using a control group and an AGE stimulated group, and the results 
revealed that Akt demonstrated a significant increase in optical densitometry when 
comparing the AGE group to the control. PI3K activity also increased significantly, and 
therefore the inhibitor study was designed to include the Akt/PI3K pathway. We began 
the study after researching many companies for Akt inhibitors. The first experiment 
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performed involved the use of Akt IV inhibitor , which was purchased from EMD 
Biosciences (San Diego , CA). The first few sets of assays using Akt IV inhibitor had 
unexplainable results , and probably are an indication of improper technique in 
performing the apoptosis assay. The results of these are shown in Figures 16&17. 
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Figure 16. Apoptosis assay done using different Akt IV inhibitor concentrations. 
Experimental cells were treated with Akt IV inhibitor one hour prior to AGE or 
collagen stimulation. Concentrations of Akt IV used were lOµM and 20µM. X-axis 
represents cell stimulus, while Y-axis represents optical density in terms of 
absorbance value. First experimental apoptosis assay done. 
50 
Figure 16 indicates that a minimal difference in absorbance values was present when 
comparing the control , collagen , AGE and inhibitor groups. 
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Figure 17. The same experiment seen in Figure 5 was attempted. This time 
collagen was treated with 20µM of Akt IV inhibitor instead of lOµM of inhibitor. 
All other conditions remained the same. X-axis represents cell stimulus, while Y -
axis represents optical density in terms of absorbance value. Experimental cells 
were treated with inhibitor one hour prior to stimulation with AGE or collagen . 
As seen in the experiment represented by Figure 17, this assay also had a peculiar 
outcome . The results are not reliable because the AGE group shows a lower optical 
density than the control and collagen control. Studies have repeatedly proven that AGE 
increases apoptosis by at least 3-fold , and this data suggests an impossible finding. The 
experiment was again repeated three times with consistent results. (Figure 18) 
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Figure 18. The x-axis represents the stimulus and the y-axis represents the 
absorbance value obtained when measuring the wavelength on a plate reader. Akt 
IV inhibitor, a non-specific Akt inhibitor, was used at a toµM concentration. 
Inhibitor group treated one hour prior to CML (AGE) stimulation. 
Figure 18 represents the results of Akt IV inhibitor on AGE stimulation in fibroblasts. 
Three different experiments were performed to confirm the results of the study, and it 
was found that this inhibitor produced unexpected results. Previous literature has 
indicated that Akt is anti-apoptotic rather than pro-apoptotic. Clearly, these results 
indicated an opposite effect than what was suspected. In this set of apoptosis assay 
experiments, Akt inhibition prevented apoptosis. Upon researching the situation further, 
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we found that the inhibitor used was weakly selective for Akt. That being said , we 
researched companies to see if a highly specific Akt inhibitor was available. The 
literature indicated that Triciribine (TCN) fit this description and a second experiment 
was performed using this inhibitor. (See Figure 19) 
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Figure 19. The results of Akt inhibitor studies using the highly selective inhibitor 
for Akt, Triciribine. Study was conducted with 3 different concentrations of TCN 
(Akt inhibitor) acting on CML stimulated fibroblasts: SµM, lOµM, and 20µM. X-
axis represents cell stimulus. Y-axis represents optical density in terms of 
absorbance value (wavelength). Inhibitor group treated one hour prior to CML 
stimulation. 
Figure 19 demonstrates a pro-apoptotic effect in the presence of a highly selective Akt 
inhibitor. The graph in figure 19 indicates that a higher dosage of inhibitor propagates an 
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increased effect on apoptosis, which substantiates reports that when Akt is 
phosphorylated, it suppresses cellular death. Since the results of the two different Akt 
inhibitors contraindicated each other , we decided to investigate the activation of Akt 
upstream by inhibiting the PI3K pathway. As can be seen in Figure 8, the 
phosphorylation of Akt is dependent upon PI3K activation. Therefore , to validate the 
results of the TCN inhibitor study, we inhibited PI3 K. If the TCN inhibitor results were 
accurate, we should anticipate that inhibition of Pl3K would coincide with those results 
shown in Figure 19. (See Figure 20) 
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Figure 20. PI3K inhibitor, LY294002, used in three concentrations: SµM, lOµM, 
and 20µM. Y-axis represents optical density in terms of absorbance value. X-axis 
represents cell stimulus. Inhibitor group treated one hour prior to CML 
stimulation. 
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Figure 20 represents treatment of fibroblasts with a highly selective PI3K inhibitor prior 
to stimulation with AGE/CML. The PI3K inhibitor, aka L Y294002, was purchased from 
LC Laboratories (Woburn, MA). As was expected, the results from this assay were 
similar to those shown with TCN (Akt selective) inhibition, which confirms the initial 
assumption that Akt suppresses cellular death rather than enhances it. The results of both 
the Akt and PI3K inhibitor study means that inhibiting the Akt pathway whether 
upstream (PI3K) or downstream (Akt itself), can increase apoptosis. 
p38 Pathway 
The next pathway we studied was the p38 pathway. The 2.74 fold increase in 
phosphorylation, obtained during the Kinexus study, was a significant change to render 
an investigation into the role of p38 in fibroblast apoptosis (Table 3). Both inhibitors 
were purchased from EMO Biosciences. We used a less highly selective inhibitor named 
ML3403 (p38 MAPK inhibitor III), and the highly specific p38 MAPK inhibitor, 
SB203580. Figure 21 demonstrates the results of this apoptosis assay series. 
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Figure 21. p38 MAPK inhibitors, ML3403 and SB203580, tested at 3 
concentrations: lOµM, 20µM, and 30µM. Y-axis represents optical density in terms 
of absorbance value. X-axis represents fibroblast stimulus. Inhibitor group treated 
one hour prior to CML stimulation. 
The results of the p38 kinase inhibitor experiments, exhibited in Figure 21, indicate that 
cutting this kinase causes a partial decrease in apoptosis. As the concentration of 
inhibitor increased , substantial suppression of apoptosis was obtained. Both inhibitors 
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tested, ML3403 and SB203580, manifested comparable data. Close analysis of the 
optical density measurements reveals that the amount by which apoptosis decreased was 
marginal. 
ERKJ/2 Pathway 
The next pathway studied was the ERKl/2 pathway. Kinexus results revealed a 12.4 fold 
increase in ERK 1 phosphorylation when AGE stimulation occurred, and a 40.24 fold 
increase in ERK 2 phosphorylation under the same conditions (Table 3). PD98059 was 
purchased from EMO Biosciences, which has been well documented to have been used 
by many researchers. However, PD98059 inhibits activation of inactive MEKl/2, and 
therefore is selective for MEKl/2 and only weakly selective for ERKl/2. Extensive 
literature review disclosed that a highly selective inhibitor of ERKl/2 does not yet exist. 
Therefore, this inhibitor was purchased and tested and the results are present in Figure 22. 
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Figure 22. PD98059, a weakly selective ERKl/2 inhibitor, was tested at three 
different concentrations: lOµM, 20µM, and 30µM. Y-axis represents optical density 
in terms of absorbance value. X-axis represents cell stimulus. Inhibitor group 
treated one hour prior to CML stimulation. 
The results in Figure 22 show that in the presence of the inhibitor PD98059 , there was 
not a prominent effect on enhancement or prevention of apoptosis. Compared to the 
results of AGE stimulated fibroblasts , the experimental inhibitor group did not change 
significantly. The optical density remained within a 0.1 absorbance value of the AGE 
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stimulated value. Based on the Kinexus study, the results of the inhibitor study were 
unforeseen. The substantial increase in phosphorylation of ERK 1 and ERK 2, when 
fibroblasts were stimulated with CML, appeared to indicate a specific role of these 
kinases in apoptosis. However, based on these results, a specific function in apoptosis 
cannot be declared. 
JNK Pathway 
The final pathway investigated was the JNK pathway. Kinexus results showed that a 
5.38 increase in phosphorylation occurred when fibroblasts were stimulated with CML 
(Table 3). Both JNK inhibitors were purchased from EMD Biosciences. Many 
different JNK inhibitors exist, but two JNK inhibitors were purchased based on method 
of pathway suppression. JNK-I diminishes signaling by blocking the activation of the 
transcription factor c-jun; JNK-ll inhibits the phosphorylation of c-jun and blocks IL-1 
induced accumulation of phospho-jun and induction of c-jun transcription. 68•69 Both 
inhibitors are highly selective for JNK. The results are represented in Figures 23 and 24. 
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Figure 23. JNK inhibitor I stimulation using three concentrations: lOµM, 20µM, 
and 30µM. X-axis represents fibroblast stimulus. Y-axis represents optical density 
in terms of absorbance value (wavelength). Inhibitor group treated one hour prior 
to CML stimulation. 
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Figure 23 indicates a decrease in apoptosis upon JNK I inhibitor treatment one hour prior 
AGE stimulation. To confirm these results , a second inhibitor was used , JNK II. Results 
are shown in Figure 24. 
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Figure 24. JNK inhibitor II tested at three concentrations: 20µM, 30µM, and 40µM. 
Concentrations chosen based on reference articles provided by EMD Bioscience. X-
axis indicates cell stimulus. Y-axis indicates optical density in terms of absorbance 
value. Inhibitor group treated one hour prior to CML stimulation. 
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Figures 23 and 24 both demonstrate similar results, which indicates that in the presence 
of both JNK I&II inhibitors, apoptosis was suppressed. The different methods of 
inhibition did not have a strong correlation with how much apoptotic suppress10n 
occurred as seen with varymg inhibitor concentrations. As the JNK inhibitor 
concentration increased, hindrance of cellular death intensified. At lower concentrations, 
a 1.5-2 fold decrease in optical density values existed when comparing the results of 
AGE stimulated fibroblasts to those of inhibitor-treated, CML-inoculated fibroblasts. As 
the concentrations increased, a compelling difference in absorbance values was 
discernible. As much as a 3-fold decrease in apoptosis occurred, when cells were treated 
with 30-40µM of JNK inhibitor. This data corresponds with literature written by other 
researchers, since it indicates that phosphorylation of the c-Jun kinase has a pro-apoptotic 
effect. 
A graph summarizing all inhibitors tested in this study is present in Figure 25. 
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Figure 25. A comparison graph of the results of all studies performed. JNK 
inhibitors produced a profound anti-apoptotic effect with p38 following closely 
behind. Akt and PI3K inhibitors rendered pro-apoptotic responses, while ERK did 
not show enough evidence to say it was pro or anti-apoptotic. 
Once the results from the inhibitor study were obtained , pathways were fabricated to 
incorporate this data. The pathways are represented in figures 26 and 27. 
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Figure 26. MAPK pathway with incorporation of Kinexus results and inhibitor 
study results. 
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Figure 27. Akt/PI3K pathway with Kinexus and inhibitor study results 
incorporated. The specific location of inhibition cannot be determined based on this 
study, but we can conclude that TCN (Akt selective inhibitor) increased apoptosis 
and Akt IV (non-specific Akt inhibitor) decreased apoptosis. 
65 
DISCUSSION 
Studies have shown that advanced glycation endproducts have a pro-apoptotic effect on 
many cell types, but the exact mechanisms by which this occurs still remains unclear. 
The actions of AGEs on cell death are mediated through specific receptors for AGE 
(RAG Es). 70 Since many kinase pathways are believed to contribute to cellular death, the 
goal of this study was to investigate the role with which specific kinase pathways, 
including Akt, p38, ERK, and JNK, have in AGE induced fibroblast apoptosis. The 
specific responses in this study pertain to one form of AGE known as 
Carboxymethyllysine (CML), but may apply to other non-enzymatic glycosylations. 
We have proposed that a link exists between AGE induced fibroblast apoptosis and 
impaired wound healing seen in diabetics. The fibroblast is imperative for proper wound 
healing due to its significant role in matrix deposition. Completion of tissue repair is 
contingent upon collagen deposition and scar formation by the fibroblast. Because 
damaged fibroblasts impair wound healing in diabetics, we selected the adult dermal 
fibroblast to study the role of the mitogen-activated kinase (MAPK) and Akt pathways in 
AGE induced apoptosis. We chose to investigate the MAP kinase pathways because of 
its well-established role in promoting cell death through JNK and p38 and cell survival 
through ERK in mesenchymal cells such as fibroblasts. Similarly, Akt was examined 
because it is well known to stimulate survival and deactivate FOXO 1. 
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In the early stages of diabetes , we see decreased chemotaxis of inflammatory cells into 
the wound, compounded by decreased phagocytosis and intracellular killing, leading to 
diminished availability of factors critical for effective wound repair. 71-75 This decreased 
influx of macrophages and neutrophils inhibits the release of cytokines, growth factors, 
and nitric oxide that induce nearby keratinocytes to migrate across the wounded 
epithelium and allow for re-epithelialization. 141 However, during the later stages of 
diabetes, inflammatory cell recruitment increases. At this point , the sustained generation 
of pro-inflammatory cytokines such as tumor necrosis factor (TNF-a) and the production 
of tissue destructive matrix metalloproteinases (MMPs) limits effective wound closure. 71 
Goova et al. concluded in their study that RAGE is involved in a cascade of events that 
disturbs the equilibrium between beneficial and injurious inflammation in the diabetic 
wound. 71 Chevakis et al. also demonstrated that the RAGE-mediated leukocyte 
recruitment was more prominent in diabetic mice, which becomes important as RAGE 
expression increases at the site of inflammation. 143 An increased RAGE expression will 
lead to further RAGE-dependent cellular activation and dysfunction; engagement of 
RAGE by its ligands, such as AGE, thereby increases the permeability of the vascular 
endothelium and may elevate the expression of adhesion molecules, such as VCAM-1, 
procoagulant tissue factor, or proinflammatory interleukin-6 probably through NF-kB 
pathways. 143-51 This may help explain the reason we see increased inflammatory cell 
recruitment as diabetes progresses. 
Programmed cellular death may also have a significant role in impaired wound healing 
among the diabetic population. During the later stages of normal physiologic wound 
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healings, fibroblasts are removed by apoptosis; however excessive apoptosis of 
repopulating fibroblasts may inhibit this repair process .142 In vitro and in vivo studies 
have confirmed increased apoptotic activity in fibroblasts treated with advanced 
glycosylated end products. 64 This is important in the diabetic patient as prolonged 
hyperglycemia results in formation of these products. Liu et. al reported the presence of 
fibroblast apoptosis during all phases of the healing response, which was particularly 
prominent during the peak healing phase in diabetic mice . 142 Present data show that 
AGEs induce apoptosis of endothelial cells, pericytes and fibroblasts , and the process 
involves oxidative stress induced activation of NF-kB, caspase-3, caspase-8, and caspase-
9.34 ·64 AGEs interfere with both extracellular matrix through inappropriate cross-linking 
of matrix proteins, and with cellular function via cell surface receptor-mediated 
interactions. 76 Chronic accumulation of these products within the skin and 
subcutaneous elements may interfere with the entry of blood and tissue-derived 
inflammatory cells such as mononuclear phagocytes (MPs) into the wound site; once in 
the wound, however, RAGE bearing MPs and other cellular effector cells, such as 
lymphocytes, endothelial cells, and fibroblasts, interact with AGEs and EN-RAGEs (the 
latter released from invading inflammatory cells) in a sustained manner. 71 
AGES can induce fibroblast apoptosis via different mechanisms. They can bind to 
receptors for advanced glycosylated end products (RAGEs), which increase in abundance 
during the diabetic state, and produce a cascade effect. 26 Once AGEs bind to receptors 
found on various cell types, activation of transcription factors and caspases occurs. This 
results in the formation of destructive cytokines and free radicals (ROS) that lead to 
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tissue damage. The formation of inflammatory cytokines and stress responses can 
activate intracellular cell-signaling pathways leading to programmed cellular death. In 
this study we focused on researching the pathways by which apoptosis occurred when 
fibroblasts were stimulated with CML. To our knowledge, this is the first study in which 
the involvement of intracellular pathways in the adult dermal fibroblast apoptosis has 
been documented. 
MAPK pathways participate in signaling cascades activated by cytokines or growth 
factors to mediate generation of specific biologic responses. 77 These pathways, which 
include JNK, ERK, and p38, have been implicated in many processes including cell 
proliferation and programmed cellular death. The role of JNK in apoptosis is complex. 
JNK phosphorylates and regulates the activity of transcription factors including c-Jun, 
ATF2, Elk-1, p53 and c-Myc and non-transcription factors, such as Bcl-2, Bcl-xL, Bim 
and BAD, in response to a variety of extracellular stimuli; in the absence of NF-t<B 
activation, prolonged JNK activation contributes to TNF-ct induced apoptosis. 152 P38 
MAP kinase signaling plays a crucial role not only in activation of caspase 8, but also in 
downstream events leading to the release of cytochrome c and activation of caspases 9 
and 3. 153 Caspase 3 is a key executioner of apoptosis, whose activation is mediated by 
the initiator caspases, caspase-8 and caspase-9. 154 In contrast to JNK and p38, ERK is 
believed to be anti-apoptotic. Ras-Raf interaction induces membrane translocation and 
activation of Raf, which then stimulates MAPK/ERK kinases (MEKs ). 155 MEKs 
phosphorylate ERK.I and ERK2, and this ERK activation is followed by phosphorylation 
of transcription factors such as BAD, which maintain protection from apoptosis. 155•156 
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Nakamura et al. demonstrated that ERK in osteoclasts is involved in their survival and 
may be involved in the formation of a ruffled border and the maintenance of cell 
polarity. 155 Studies have also shown that the Akt pathway may have a role in cell 
survival. One function of Akt is phosphorylation of BAD and Caspase 9 by Akt, which 
suppresses their proapoptotic function within the cytoplasm. 147 Akt-dependent 
phosphorylation also inactivates FKHRLl as well as FKHR function (members of the 
Forkhead transcription factor family), and therefore suppresses the transcription of death 
genes, such as the Fas ligand gene, and thereby promotes cell survival. 157-53 
Based on the well-known role of these pathways in cell apoptosis and survival, we 
decided to test the role of these three major MAPK pathways and the Akt pathway in 
AGE induced fibroblast apoptosis. Before beginning our inhibitor study, protein 
extraction experiments were carried out to confirm increased phosphorylation in the 
kinases of interest. A western blot analysis was performed by KINEXUS, which 
revealed increased phosphorylation in all three MAPKs when stimulated with advanced 
glycosylated end products. 
The first inhibitor study performed tested the role of the Akt pathway in CML induced 
fibroblast apoptosis. In addition to the inhibition of pro-apoptotic factors, Akt can also 
activate the transcription of anti-apoptotic genes through the activation of the 
transcription factor NFkB. 53 The initial experiments we performed produced unexpected 
results by indicating that the Akt inhibitor decreased apoptosis. This would suggest that 
Akt was involved in apoptosis. As previously stated, prior researchers have reported a 
role of Akt in cell survival. Upon further investigation, we learned that the Akt IV 
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inhibitor purchased from Calbiochem was not highly specific for Akt. This inhibitor may 
have been more specific for pro-apoptotic proteases such as Caspase 9 and AFX, which 
might explain the anti-apoptotic effect we saw when stimulating the CML-collagen cells 
using this Akt IV inhibitor. Therefore, we searched for a highly specific inhibitor and 
purchased Triciribine (TCN). When the apoptosis assay was retested using TCN, we 
found that the inhibitor increased CML-collagen induced apoptosis, which supports 
previous studies and suggests Akt involvement in cell survival rather than apoptosis. 
Since we found opposite effects using two different Akt inhibitors, we decided to 
investigate the pathway upstream and test PI3K. Phosphorylation of PI3K activates Akt 
(see Figure 7). The apoptosis assays performed using a PI3K inhibitor paralleled the 
results seen when TCN was tested. Since the PB K inhibitor also increased CML-
collagen induced apoptosis, we are confident with the findings of the TCN experiments. 
These results indicate that, indeed, Akt has a role in suppression of fibroblast apoptosis. 
Both the TCN and PI3K studies demonstrated that CML-collagen stimulated fibroblasts 
also resulted in increased apoptosis, which supports previous studies that indicate AGEs 
. l d . . 11 9 121 122 are mvo ve m apoptos1s. ' ' 
P38 MAPK signaling cascades are activated in response to cellular stress and cytokines 
via the activation ofG protein coupled receptors and are known to be involved in 
apoptosis. 79•80 A well-known downstream target of p38 MAPK is NF-kB, which has 
been found to induce transcription of several anti-apoptotic genes, including the one 
encoding FLICE-inhibitory protein. 81-84 Most studies have suggested that p38 is a pro-
apoptotic kinase, but limited studies demonstrate the role of p38 in cell survival due to 
71 
cell specific responses. Zechner et. al demonstrated that MKK.6-mediated activation of 
p38 MAP kinase leads to the protection of cardiac myocytes from apoptosis, and 
therefore results in growth and survival of these cells. 47 Our study focused specifically 
on the role ofp38 in apoptosis of adult dermal fibroblasts. We tested a specific p38 
inhibitor and a less specific inhibitor to avoid the complications seen in the Akt inhibitor 
study. A less specific p38 inhibitor may have an effect on Fas receptors as activation of 
p38 is believed to protect cells from apoptosis through the down-regulation of the Fas 
receptor expression. 163 As in the Akt and PBK study, fibroblasts stimulated with CML-
collagen demonstrated increased apoptosis. Use of two different p38 inhibitors 
demonstrated similar results. We found that in the presence of a p3 8 inhibitor, apoptotic 
activity decreases when fibroblasts are stimulated with CML-collagen. This data 
supports other research by suggesting that p38 MAPKs have a pro-apoptotic effect on 
adult dermal fibroblasts. 159-62 
Studies have been conducted to identify the role of the ERK pathway in different cell 
types. Typically, the protein Raf induces the transcription of anti-apoptotic genes such as 
Bcl-2 and subsequent activation of the Raf/MEK/ERK pathway results in the 
phosphorylation and inactivation of the pro-apoptotic Bad protein. 85 While most studies 
indicate a role of ERK in cell survival, cell specific responses in T-cells, neurons, and 
d . h d d l f ERK . . 164-66 H . . car iac myocytes ave emonstrate a ro e o m apoptos1s. owever, 1t 1s 
generally accepted that the activation of the ERK cascade leads to proliferation in cells 
such as osteoclasts, renal epithelial cells, and B-cells and delivers a survival signal which 
· f:c. 1· · db JNK d h 38 · · 86-88 155 t67 168 T counteracts pro-apoptotlc e 1ects e 1c1te y an t e p activat10n. ' ' ' o 
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investigate the role of ERK in fibroblast apoptosis, we conducted a study using a 
MEKl/2 selective inhibitor, PD98059. Phosphorylation of MEKl and MEK 2 directly 
phosphorylates ERK l and ERK 2. PD98059 is highly specific for MEKl/2 and weakly 
inhibits ERK, but does not inhibit other pathways as no associations have been 
established between MEK 1/2 and the JNK or p38 pathways. A specific ERK 1/2 
inhibitor does not exist to date, and therefore only one inhibitor was tested to study the 
ERK pathway. Upon experimentation, we found that use of the inhibitor did not show a 
significant role in either cell survival or apoptosis as absorbance values remained very 
similar to those of the AGE stimulated fibroblasts which were not treated with PD98059. 
Based on these results, we are unable to conclude whether ERK has a role in apoptosis or 
cell survival in the dermal fibroblast when stimulated with CML, which may suggest that 
ERK has little role in cell survival or apoptosis in the dermal fibroblast. 
Once activated , JNKs phosphorylate an array of different substrates ranging from 
transcription factors to apoptosis regulatory molecules, and therefore have a role in 
regulation of cell viability, cellular stress, induction of apoptosis and cell proliferation. 78 
Most studies indicate a strong role of JNK in inducing programmed cellular death, 
although a few have reported anti-apoptotic effects in cells such as B cells and p53 
deficient tumor cells. 152 These inconsistencies are due to the fact that the effect of 
activation of the JNK pathway on apoptosis depends on cell type, the nature of the death 
stimulus, the duration of its activation and probably, most importantly, the activity of 
other signaling pathways. 89 The JNK cascade was the final pathway tested in our study. 
Three types of JNK exist: type 1,2, and 3. Unlike JNK-3, whose expression is restricted 
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to brain, heart and testis, isoforms l and 2 are ubiquitously expressed. 40 '79 We tested two 
JNK inhibitors and found that both resulted in decreased apoptosis when cells were 
treated with the inhibitors one hour prior to stimulation with CML. Again, this supports 
previous studies by indicating that JNK has a role in inducing apoptosis. 152, 169-70 
What does all of this imply? Based on the results in this study, we can conclude that 
CML-collagen stimulates apoptosis in adult dermal fibroblasts. These studies also 
demonstrate that apoptosis in the dermal fibroblast does occur via both the p38 and JNK 
pathways and that cell survival occurs through the Akt pathway. We can also conclude 
that ERK appears to have little role in apoptosis or cell survival based on our data. An 
in-vivo study in brain tissue was conducted by Newhouse et al, which also demonstrated 
a role of p38 and JNK in human dopaminergic cells, and therefore supports the findings 
in this study. 171 The data presented in this study will hopefully prompt future 
experimental designs, which will concentrate on the mechanisms by which p38 and JNK 
cause apoptosis in the diabetic dermal fibroblast. Identification of this process may help 
researchers understand the exact mechanisms behind the decreased wound healing seen 
in the diabetic patient. Although we have identified the pathways through which 
apoptosis occurs in the fibroblast, the mechanisms by which this occurs still remains 
unclear. Further studies should be conducted to obtain this information. The limitations 
encountered in this study were that a specific ERK inhibitor does not exist, and therefore 
we were unable to detect the role of this kinase pathway in apoptosis or cell survival. 
Perhaps use of a more specific ERK inhibitor, once developed, would help specify the 
role of this kinase in programmed cellular death. Until that time, we can conclude that 
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the role of p38 and JNK in the dermal fibroblast apoptosis may significantly influence 
wound healing in diabetic patients, while Akt signaling pathways provide a role in cell 
survival. 
The role of JNK and p38 in fibroblast apoptosis may have significant clinical 
implications in the diabetic patient seeking endodontic therapy. Inflammation and 
destruction of the periodontal ligament (PDL) and surrounding bone are sequelae to the 
spread of toxins from the necrotic pulp into the periradicular tissue. As patients 
commonly present with primary endodontic as well as combined periodontal/endodontic 
lesions, removal of bacteria via endodontic and/or periodontal therapy provides a positive 
environment for bone and PDL regeneration. As we have discussed, diabetic patients 
exhibit increased levels of advanced glycosylated end products as a result of the chronic 
hyperglycemic state associated with this disease. The results of this study indicate a role 
of advanced glycosylated end products in dermal fibroblast apoptosis through JNK and 
p38 signaling pathways. We speculate that these pathways may also have a role in 
apoptosis of periodontal ligament fibroblasts in the diabetic patient, and therefore may 
have an adverse affect on the ability of endodontic or periodontal/endodontic lesions to 
completely heal in this patient population. Similarly, these patients also may not be 
appropriate candidates for intentional replantation cases due to the limited ability of PDL 
fibroblasts to proliferate and regenerate fibers for cementum attachment. As obesity has 
reached epidemic proportions in the United States, more children are also being 
diagnosed with Type II Diabetes Mellitus than ever. This may have grave ramifications 
in diabetic children who have presented with an avulsed tooth. The incidence of external 
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root resorption increases with longer extra-oral dry times due to the inability to 
regenerate in the presence of dried PDL cells. However, the results of this study may 
suggest that an even higher risk of external root resorption in the diabetic population due 
to the possible role of JNK and p38 in PDL fibroblast apoptosis. 
Recent studies have also demonstrated the role of the JNK and p38 pathways in 
bl · 171 osteo ast apoptos1s. 
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